Lilly Aims For Earlier Treatment With Novel Diabetes Drugs
GLP-1/GIP Agonist Tirzepatide Leads Next-Gen Pipeline
Executive Summary
Lilly outlined its tirzepatide-led pipeline of incretin agonists and highlighted its once-weekly basal insulin during a post-ADA event. The company hopes to grow the GLP-1 market overall rather than shift patients from Trulicity.
You may also be interested in...
Novo Reaches Winning Post With Gamechanger Once-Weekly Insulin
The Danish drugmaker is cementing its leadership in diabetes with an imminent approval in Europe for Awiqli which reduces the number of basal insulin injections for patients from seven to just one per week.
Novo Nordisk’s Once-Weekly Insulin Gains Superiority Finding As Lilly Advances
The ONWARDS 1 and 6 results closely follow success in ONWARDS 2 in April, further helping strengthen insulin icodec’s potential market position, but Lilly is nipping at Novo’s heels.
Five (Non-COVID) Clinical Trial Hits Of 2021
2021 may have been dominated by the continuing coronavirus pandemic, but that did not stop industry’s more bread and butter R&D activities. Here, In Vivo takes a look at five of the more notable clinical trial hits of the year.